Precursor Condition
Vulvar Intraepithelial Neoplasia
CI-CAN-00004266VINExplore in graph →
Precursor4 active trials
- NCIt
- C4756
Loading cancer entity…
Loading cancer entity…
Precursor Condition
CI-CAN-00004266VINExplore in graph →
Clinical trials
34 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 |
| clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT01861535 | Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia(PITVIN) | completed | Phase 3 | 110 | Medical University of GrazOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT01735006 | Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine | completed | Phase 3 | 7,372 | Xiamen UniversityOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02562508 | A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls | completed | Phase 3 | 979 | Jun ZhangOTHER | 1 | Aug 16, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jun 7, 2024source: clinicaltrials